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Invited Commentary 
M a r k  B. Or r inge r ,  M.D .  
Section of Thoracic Surgery, The University of Michigan, Ann 
Arbor, Michigan, U.S.A. 
I congratulate Dr. Nishimaki and associates for their interest- 
ing, carefully documented, thought-provoking report  on super- 
ficial " ea r ly"  esophageal cancer. Their operative results (only 2 
postoperative deaths among 89 esophagectomies) are com- 
mendable. This study draws immediate attention to one of the 
several deficits of the currently utilized TNM staging system for 
esophageal carcinoma: not all tumors staged as T1 have similar 
biologic behavior. T1 tumors include intraepithelial (EP), intra- 
mucosal invasive (MM), and submucosal invasive (SM) carci- 
nomas, but lymph node metastases are rare with EP and MM 
tumors and not with SM tumors. The authors report  no lymph 
node metastases in any of their EP or MM tumors, whereas 41% 
of the SM tumors (24 of 88) had at least a few lymph node 
metastases (92% had three or fewer positive lymph nodes). In 
addition, SM carcinomas were significantly larger and had 
significantly more circumferential spread, intraductal micro- 
scopic spread, and vascular invasion than the EP or MM 
tumors. As might be anticipated, the disease-specific survivals 
for patients with EP and MM carcinomas were 100% at both 3 
years and 5 years, and those for SM cancers were 71% at 3 
years and 64% at 5 years, respectively. These data, which 
demonstrate the different clinical characteristics of mucosal (EP 
and MM) versus submucosal (SM) carcinomas, are viewed by 
the authors as justification for their recommendation that sur- 
gical therapy for these tumors should be different. They pro- 
pose that lymphadenectomy is not needed for mucosal cancers, 
for which a transhiatal esophagectomy or even a limited muco- 
sal resection is adequate. For  those invading the submucosa, 
however, a transthoracic esophagectomy is indicated. If the 
tumor is in the upper esophagus, a bilateral cervical and 
mediastinal lymphadenectomy should be performed; for lower 
esophageal tumors, a mediastinal and abdominal lymphadenec- 
tomy; and for midesophageal SM carcinomas, bilateral cervical, 
mediastinal, and abdominal (three-field) lymphadenectomy. 
Such recommendations,  in my opinion, represent quantum and 
unjustified extrapolations from the available data. 
As a long-standing proponent of transhiatal esophagectomy 
for esophageal carcinoma, I find the suggestion that we treat 
systemic disease surgically untenable and pass› We have 
witnessed the age-old golden tenets of the Halsted radical 
mastectomy for breast  carcinoma crumble under the scrutiny of 
controlled, prospective,  randomized comparison with less ex- 
tensive operations. The concept that the larger operation (the 
wider the en bloc resection and the more lymph nodes resected) 
is the better cancer operation has been abandoned by most 
oncologic surgeons for pancreatic cancer, melanoma, and vir- 
tually every neoplasm. The extensive mediastinal lymphatic 
drainage is responsible for the early spread of most esophageal 
cancers and their dismal cure rate. One has only to look at 
Table 2 of Nishimaki 's  report to see the frightening number of 
nodal metastases even in this patient population with presumed 
"ea r ly"  esophageal cancer. 
I have serious concerns about the radical surgery recom- 
mended by the authors on the basis of  their data. Operative 
therapy in these 89 patients with superficial esophageal carci- 
noma was not standardized: 52 undergoing transthoracic esoph- 
agectomy and 33 transhiatal esophagectomy. In the latter 
group, the true incidence of lymph node metastases cannot be 
determined. Did the survival among these two groups undergo- 
ing different types of esophagectomy vary significantly? Only 
28% of these patients (approximately 30%) underwent three- 
field lymphadenectomy, so again the true incidence of lymph 
node metastases in this series is unknown. Postoperative ther- 
apy was similarly not uniform: 27 patients with SM carcinoma 
received adjuvant therapy (chemotherapy, radiation therapy, or 
both). Therefore it is impossible to determine if the survival 
obtained reflects the results of operative or systemic treatment. 
A median follow-up of only 28 months in this group is too short 
to draw meaningful conclusions about "long-term cure ,"  as 
metastases from these small TI tumors may take longer to 
become evident than with more advanced tumors. Finally, 
there is no mention by the authors of the morbidity of three-field 
lymphadenectomy when it used as an adjunct to esophagec- 
tomy. Is the incidence of postoperative respiratory distress and 
the need for prolonged mechanical ventilation increased by 
vigorous dissection of the mediastinal and tracheobronchial 
772 Worid J. Surg. Vol. 17, No. 6, Nov./Dec. 1993 
lymphatics? Is the incidence of chylothorax increased? How 
many patients sustained recurrent laryngeal nerve injury during 
the process of the bilateral cervical and extensive mediastinal 
lymphadenectomy, and what is the price of this problem in 
terms of aspiration and difficulty swallowing postoperatively? 
What is the length of hospitalization, and how many days were 
spent in the intensive care after such radical surgery? Is the 
increased length of hospitalization justified by truly improved 
survival? Is such a radical operative approach worth the effort 
for an average of three or fewer positive lymph nodes? 
In most patients with esophageal cancer, lymphadenectomy 
can diagnose tumor stage; itis hot therapeutic, as implied by the 
authors. The real problem is that by the time we begin to 
"stage" esophageal cancer on the basis of clinicopathologic 
findings, regardless of how "early" a tumor we diagnose, the 
genetic changes that induced that tumor have already occurred, 
and we are hOt dealing with "early" carcinoma, even with T1 
lesions. It is time to stop counting lymph nodes when assessing 
the merits of therapy for esophageal carcinoma. As we continue 
to identify the genetic events responsible for the development 
of esophageal carcinoma, we may soon have the ability to 
detect the critical genetic markers indicative of impending 
malignant degeneration in high risk patients. Specific gene 
therapy may then be directed at truly early premalignant 
change. Until this becomes a reality, our survival data obtained 
with transhiatal esophagectomy support our current approach. 
If the esophageal carcinoma has not metastasized, it will likely 
be cured by transhiatal esophagectomy. If metastases have 
occurred, however, esophagectomy alone, regardless of how 
many lymph nodes are removed, is unlikely to achieve cure. 
Again, I congratulate Nishimaki and associates for this fine 
report. For me, however, if you will pardon the pun, their 
recommendations are hard to swallow. 
